Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - ascopubs.org
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Twenty percent of patients with follicular
lymphoma (FL) experience progression of disease (POD) within 2 years of initial …
lymphoma (FL) experience progression of disease (POD) within 2 years of initial …
[HTML][HTML] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An …
C Casulo, M Byrtek, KL Dawson… - Journal of clinical …, 2015 - pubmed.ncbi.nlm.nih.gov
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - europepmc.org
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis …
C Casulo, M Byrtek, KL Dawson… - Journal of Clinical …, 2015 - mayoclinic.elsevierpure.com
Purpose: Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
[PDF][PDF] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for …
C Casulo, M Byrtek, KL Dawson, X Zhou, CM Farber… - J Clin …, 2015 - researchgate.net
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
[HTML][HTML] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of clinical …, 2015 - iro.uiowa.edu
Twenty percent of patients with follicular lymphoma (FL) experience progression of disease
(POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the National …
(POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the National …
Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis …
C Casulo, M Byrtek, KL Dawson… - Journal of …, 2015 - mdanderson.elsevierpure.com
Purpose: Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …